Table 3 Treatment characteristics (n = 94)
From: From IB2 to IIIB locally advanced cervical cancers: report of a ten-year experience
Characteristics | Whole set of patients (n = 94) | Complete CCRT (n = 41) | Incomplete CCRT (n = 53) | p-value |
|---|---|---|---|---|
Pelvic external radiation therapy, n (%) | 94 (100) | 41 (100) | 53 (100) | NS |
Total dose, median (IQR) | 46 (46–48) | 46 (46–48) | 46 (46–48) | NS |
Total dose boost, median (IQR) | 55 (54–56) | 56 (54–56) | 56 (54–57) | NS |
Fractions, median (IQR) | 23 (23–25) | 23 (23–25) | 23 (23–25) | NS |
Para aortic external radiation therapy, n (%) | 3 (3.2) | 1 (2.4) | 2 (3.8) | NS |
Radiotherapy technique | ||||
3D–CRT, n (%) | 57 (60.6) | 26 (63.4) | 31 (58.5) | NS |
IMRT, VMAT, n (%) | 37 (39.4) | 15 (36.6) | 22 (41.5) | |
Concurrent chemotherapy, n (%) | 81 (86.2) | 41 (100) | 40 (75.5) | < 0.01a |
Number of cycles ≥ 4, n (%) | 69 (73.4) | 41 (100) | 28 (52.8) | < 0.01a |
Cisplatin, n (%) | 64 (68.1) | 34 (82.9) | 30 (56.6) | < 0.01b |
Carboplatin, n (%) | 22 (23.4) | 11 (26.8) | 11 (20.8) | NS |
Brachytherapy, n (%) | 73 (77.7) | 41 (100) | 32 (60.4) | < 0.01a |
PDR, n (%) | 72 (76.6) | 40 (97.6) | 32 (60.4) | < 0.01b |
HDR, n (%) | 1 (1.1) | 1 (2.4) | 0 (0) | NS |
Dose (Gy), median (IQR) | 25 (24–30) | 26 (24–30) | 25 (24–30) | NS |
OTT (days), median (IQR) | 56 (50–63) | 55 (50–64) | 56 (53–62) | NS |
Surgery, n (%) | 77 (81.9) | 35 (85.4) | 42 (79.2) | NS |
CHL, n (%) | 55 (58.5) | 27 (65.9) | 28 (52.8) | NS |
CHL and para aortic lymphadenectomy, n (%) | 7 (7.4) | 5 (12.2) | 2 (3.8) | NS |
Other, n (%) | 15 (16) | 2 (4.9) | 11 (20.8) | < 0.03a |
Time between brachytherapy and surgery (days), median (IQR) | 42 (36–57) | 42 (34–53) | 45 (38–57) | NS |